ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMA
Previous Symbol
CUSIPN/A
Phone201-478-5552
Debt
Debt-to-Equity Ratio1.11
Current Ratio6.32
Quick Ratio4.92
Price-To-Earnings
Trailing P/E Ratio-2.54
Forward P/E Ratio-3.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.76 million
Price / Sales9.88
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.89 per share
Price / Book5.45
Profitability
EPS (Most Recent Fiscal Year)($1.91)
Net Income$-43,750,000.00
Net Margins-243.42%
Return on Equity-155.19%
Return on Assets-55.85%
Miscellaneous
Employees295
Outstanding Shares46,350,000
Market Cap$221.09 million
OptionableOptionable
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) issued its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.02. The biotechnology company had revenue of $4.23 million for the quarter, compared to analyst estimates of $5.39 million. ADMA Biologics had a negative net margin of 243.42% and a negative return on equity of 155.19%. View ADMA Biologics' Earnings History.
When is ADMA Biologics' next earnings date?
What price target have analysts set for ADMA?
6 Wall Street analysts have issued 12 month price targets for ADMA Biologics' shares. Their forecasts range from $7.50 to $17.00. On average, they anticipate ADMA Biologics' share price to reach $11.5833 in the next twelve months. This suggests a possible upside of 142.8% from the stock's current price. View Analyst Price Targets for ADMA Biologics.
What is the consensus analysts' recommendation for ADMA Biologics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.
What are Wall Street analysts saying about ADMA Biologics stock?
Here are some recent quotes from research analysts about ADMA Biologics stock:
- 1. HC Wainwright analysts commented, "Our price target of $3/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing. Bellerophon Therapeutics, Inc." (11/9/2018)
- 2. Maxim Group analysts commented, "ADMA announced that FDA has accepted the BLA resubmission for RI-002, the company’s specialized IVIG immunoglobulin for Primary Immune Deficiency Disease (PIDD) and assigned a PDUFA date on April 2, 2019." (10/17/2018)
Has ADMA Biologics been receiving favorable news coverage?
News articles about ADMA stock have trended somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ADMA Biologics earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include Novavax (NVAX), Solid Biosciences (SLDB), Cellectis (CLLS), DBV TECHNOLOGIE/S (DBVT), Acorda Therapeutics (ACOR), Vericel (VCEL), Heska (HSKA), Gritstone Oncology (GRTS), Scholar Rock (SRRK), BAVARIAN NORDIC/S (BVNRY), Coherus Biosciences (CHRS), Twist Bioscience (TWST), Avrobio (AVRO), Adaptimmune Therapeutics (ADAP) and NanoString Technologies (NSTG).
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 41)
- Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 70)
- Mr. Brian Lenz, VP & CFO (Age 46)
- Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 72)
- Mr. James Hauert, Sr. VP of Commercialization & Strategy
Who are ADMA Biologics' major shareholders?
ADMA Biologics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.57%), BlackRock Inc. (2.07%), JPMorgan Chase & Co. (0.49%), JPMorgan Chase & Co. (0.49%) and Renaissance Technologies LLC (0.41%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Institutional Ownership Trends for ADMA Biologics.
Which institutional investors are selling ADMA Biologics stock?
Which institutional investors are buying ADMA Biologics stock?
ADMA stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, JPMorgan Chase & Co., JPMorgan Chase & Co. and Vanguard Group Inc.. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Insider Buying and Selling for ADMA Biologics.
How do I buy shares of ADMA Biologics?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA stock can currently be purchased for approximately $4.77.
How big of a company is ADMA Biologics?
ADMA Biologics has a market capitalization of $221.09 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe.
What is ADMA Biologics' official website?
How can I contact ADMA Biologics?
ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]
MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
